We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Cause of Severe Insulin Resistance Found

By Biotechdaily staff writers
Posted on 07 Aug 2002
Researchers investigating the mechanisms underlying type-2 diabetes have confirmed the importance of the protein PPAR gamma and have implicated a second gene, PPP1R3A, which may lead to novel targets for new drug discovery. More...
The findings appeared in the July 15, 2002, issue of Nature Genetics.

The gene PP1R3A encodes a regulatory subunit for protein phosphatase 1. Phosphatases are known to be involved in modulating insulin signaling. In diabetics, defects in both of these genes produce severely impaired insulin responsiveness. These findings clarify the path involved in insulin responsiveness and may lead to improved diagnostic and therapeutic strategies. The study was conducted by researchers from Incyte Genomics, Inc. (Palo Alto, CA, USA) and researchers from the University of Cambridge (UK) in an ongoing collaboration.

PPAR gamma is the target of insulin-sensitizing drugs such as Actos and Avanda, reported to underlie some forms of insulin resistance by Incyte Genomics.

"These results illustrate the potential for genomic and genetic studies to shed light on the mechanisms of disease and to offer opportunities to define novel targets for innovative drug discovery,” said Robert B. Stein, M.D., Ph.D., president and chief scientific officer at Incyte.




Related Links:
Incyte
Univ. Cambridge

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Platelet Function Analyzer
PL-12
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.